Featured Company News - Myriad Genetics' EndoPredict Receives Positive Coverage Decisions from Palmetto and Anthem
Research Desk Line-up: Bioanalytical Systems Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 22, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Myriad Genetics, Inc. (NASDAQ: MYGN) ("Myriad"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MYGN. The Company announced on August 17, 2017, that it has received positive coverage decisions for EndoPredict® testing from Palmetto GBA, the Medicare contractor who oversees the MolDx program, and Anthem, Inc. Once the decisions are fully implemented, Myriad will have coverage for over 90% of breast cancer patients. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Research Services industry. Pro-TD has currently selected Bioanalytical Systems, Inc. (NASDAQ: BASI) for due-diligence and potential coverage as the Company announced on August 14, 2017, its financial results for Q3 FY17. Tune in to our site to register for a free membership, and be among the early birds that get our report on Bioanalytical Systems when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MYGN; also brushing on BASI. Go directly to your stock of interest and access today's free coverage at:
Anthem is an American private health insurance company offering a broad range of medical and specialty products. MolDx program, developed by Palmetto GBA, identifies and establishes coverage and reimbursement for molecular diagnostics tests.
EndoPredict Test Outperformed Leading First-Generation Test
Mark C. Capone, President and Chief Executive Officer of Myriad Genetics, mentioned that the Company has nearly full coverage for EndoPredict testing in the United States which was accomplished in an unprecedented time of less than six months after its launch. Mark believes that this rapid expansion of coverage reflects the strong scientific evidence and compelling head-to-head data where the EndoPredict test markedly outperformed the leading first-generation test, and the value of avoiding frustrating and costly intermediate results.
EndoPredict's Positive Coverage Strengthens the Use of Second Generation Test for Predicting Recurrence
Commenting on the positive coverage decisions for EndoPredict® testing, Johnathan Lancaster M.D., Ph.D., Chief Medical Officer of Myriad Genetics, stated that increased physician interest in EndoPredict testing and broad reimbursement has been observed, thereby strengthening the Company's conviction to use a second generation test with clear superiority in predicting recurrence in the critical five- to ten-year timeframe.
Myriad's Recent Announcement
News release suggests that on June 04, 2017, Myriad's BRACAnalysis CDx® companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD trial, which responded better to treatment with olaparib than standard chemotherapy.
EndoPredict is a gene expression test that helps patients with breast cancer to determine the best treatment option for their individual cancer. The diagnostic test accurately determines the likelihood of cancer recurrence 10 years after diagnosis, allowing physicians to decide which patients can safely forgo chemotherapy. EndoPredict has been validated in approximately 4,000 patients with node-negative and node-positive cancer and has been used clinically in over 15,000 patients.
About Myriad Genetics
Formed in 1991, Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests, for assessing persons risk of developingdisease, guide treatment decisions and assess risk of disease progression and recurrence. The Company is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. Myriad is based in Salt Lake City, Utah.
About Palmetto GBA
Palmetto GBA is one of the US's largest providers of high volume claims and transaction processing, contact center operations and technical services to the federal government and other commercial customers. Headquartered in Columbia, South Carolina, the Company employs more than 1,300 associates across the US.
Last Close Stock Review
Myriad Genetics' share price finished yesterday's trading session at $28.94, rising slightly by 0.49%. A total volume of 1.18 million shares have exchanged hands, which was higher than the 3-month average volume of 1.06 million shares. The Company's stock price soared 36.83% in the last three months, 51.68% in the past six months, and 36.06% in the previous twelve months. Additionally, the stock skyrocketed 73.61% since the start of the year. Shares of the Company have a PE ratio of 92.17 and currently have a market cap of $1.99 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.